---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Prevalence"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Prevalence. Topics: United States diagnosed and estimated prevalence from claims data; United States claims analysis: data source, methods, and author affiliations; Infantile-onset share of United States prevalent cases: sponsor statement; Undiagnosed fraction in the United States: sponsor statement; 5 further topics. 9 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/prevalence"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Prevalence

<a id="heading-2.2.1.2.2"></a>

## 2.2.1.2.2 Prevalence of Niemann-Pick disease type C

<a id="topic-2.2.1.2.2-1"></a>

### United States diagnosed and estimated prevalence from claims data

> “A total of 308 million unique individuals were represented in the database.”
> “Of these, 294 individuals had an NPC diagnosis, yielding an identified NPC prevalence of 0.95 per million people in the United States.”
> “305 individuals were diagnosed with NPC and/or were treated with miglustat without having a diagnosis for either Gaucher or GM1 gangliosidosis, yielding an NPC diagnosed or treated prevalence of 0.99 per million people in the United States.”
> “Applying this number to the distribution of NPC type (based on age of neurologic symptom onset) and corresponding mortality estimates generates an estimated 943 prevalent cases of NPC, or 2.9 cases of NPC per million people in the United States.”

Source: [Burton et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34304992/)

<a id="topic-2.2.1.2.2-2"></a>

### United States claims analysis: data source, methods, and author affiliations

> “For the first two objectives, patients were identified using the Symphony Integrated DataVerse database (Oct 2015-Jan 2020).”
> “For the third objective, published NPC incidence (1 per 89,000 live births) and expected mortality estimates were applied to the 2018 United States birth rate (11.6 per 1000) and population size (326.7 million).”
> “Blair Orr, Shilpa Chatlani, Kwangchae Yoon, and Dan Gallo are shareholders and employees of Orphazyme USA Inc.”

Source: [Burton et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34304992/)

<a id="topic-2.2.1.2.2-3"></a>

### Infantile-onset share of United States prevalent cases: sponsor statement

> “In the U.S., approximately half of those living with NPC – 475 children – have infantile-onset NPC”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="topic-2.2.1.2.2-4"></a>

### Undiagnosed fraction in the United States: sponsor statement

> “In the U.S., approximately two-thirds of people with Niemann-Pick disease, type C (NPC) remain undiagnosed”
> “Genetic testing is required to confirm the diagnosis of NPC but is often delayed due to diffuse symptoms that overlap with multiple neurological conditions as well as low disease awareness among healthcare providers.”

Source: [Beren Therapeutics test for NPC press release (2026)](https://www.berentx.com/news/beren-therapeutics-launches-test-for-npc-to-help-identify-people-with-niemann-pick-disease-type-c-who-remain-undiagnosed/)

<a id="topic-2.2.1.2.2-5"></a>

### FDA statement of disease frequency

> “Niemann-Pick disease type C (NPC) is a rare, inherited lysosomal storage disorder affecting an estimated 1 in 150,000 people, in which the body cannot properly process cholesterol and other fats inside cells.”

Source: [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)

<a id="topic-2.2.1.2.2-6"></a>

### Prevalence estimates in Western Europe and the United States

> “The prevalence of NPC has been estimated at 1:150,000 in Western Europe.”
> “The prevalence of NPC in the United States was estimated at 2.9 in one million, based on assumption of underdiagnosis and misdiagnosis”
> “The prevalence of NPC in childhood is probably underestimated, owing to the nonspecific presentations in that age group.”
> “The overall prevalence is likely higher than the calculated incidence, owing to relatively prolonged survival in those with later-onset disease, although no comprehensive data are available.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.2.2-7"></a>

### Oregon Medicaid drug evaluation statement of frequency

> “Type C affects roughly 1 in 100,000 to 150,000 people, though it may be underrecognized.”

Source: [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)

<a id="topic-2.2.1.2.2-8"></a>

### Share of adult-onset disease among prevalent cases

> “Statement #8: Adult‐onset NPC patients may represent up to a third of all NPC patients.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.2.2-9"></a>

### Diagnosed cases in Australia

> “In the absence of a national register, the number of current diagnosed cases in Australia is estimated by clinical services as between 25 and 33, although this is widely considered an underestimate, with many cases likely undetermined or in some cases misdiagnosed.”

Source: [Tchan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193484/)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
